A Five-Year Medium- to Long-Term Growth Strategy Looking 10 Years Ahead
First written in FY2017-Q3. 12 of 23 entries say "Advanced", first in FY2017. Latest entry: 2026-06-02.
No other company in this theme has enough history to compare yet.
- 2026-06-02First statedGeneral Meetings of Shareholders
「We are already working diligently on formulating our next growth strategy, GS31, and will take a new step forward toward its realization together with our shareholders.」
GS31 was presented for the first time as the next growth strategy following GS26. - FY2025AdvancedAnnual report
「We are shifting our focus from products to customers and engaging more actively with the healthcare ecosystem as a whole, driving the business with the aim of becoming a company that can propose comprehensive solutions to customers’ challenges.」
In the third year of GS26, the Group continued its shift from standalone devices to solutions. Revenue increased 12.4% and adjusted operating profit rose 29.8%, indicating progress for the fiscal year. - FY2024AdvancedAnnual report
「In December 2021, the Group formulated a growth strategy covering the next 5 years. As its medium- to long-term vision for addressing paradigm shifts in healthcare, including coexisting with chronic diseases in an aging society and the full-scale adoption of personalized medicine driven by advances in genomic medicine and AI, the Group set out the goal of “From Devices to Solutions.”」
In the second year of GS26, the Group explicitly identified responding to paradigm shifts in healthcare as the background to its growth strategy and continued its shift from standalone devices to customer-focused solutions covering the healthcare ecosystem as a whole. - FY2024-Q2AdvancedAnnual report
「Revenue was ¥443.9 billion, up 10.1% year on year. Adjusted operating profit increased 7.3% to ¥75.6 billion, as the increase in gross profit more than offset the increase in selling, general and administrative expenses.」
Under GS26, cumulative revenue for FY2024-Q2 increased 10.1% and adjusted operating profit rose 7.3%, improving from the decline in adjusted operating profit in FY2024-Q1. - FY2024-Q1Revenue growth, decline in adjusted operating profitAnnual report
「Revenue was ¥215.3 billion, up 9.1% year on year. Adjusted operating profit fell 3.9% to ¥34.5 billion, as selling, general and administrative expenses increased because of stepped-up investment in growth areas.」
Under GS26, revenue increased 9.1% in FY2024-Q1, while adjusted operating profit declined 3.9% due to increased investment in growth areas. - FY2023Revenue up, profit slightly upAnnual report
「The consolidated results for the fiscal year, which was the first year of the strategy, were as follows.」
In FY2023, the first year of GS26, revenue rose 16.6% year on year and adjusted operating profit increased 2.7%. Revenue grew strongly, while profit growth was modest. - FY2023-Q2Revenue up, profit downAnnual report
「Revenue rose 17.0% year on year to ¥403.3 billion. Adjusted operating profit fell 5.0% year on year to ¥70.4 billion.」
While revenue increased under the new 5-year growth strategy, adjusted operating profit declined due to higher manufacturing costs resulting from inflation and the normalization of sales promotion activities. - FY2022ReframedAnnual report
「In December 2021, the Group formulated a growth strategy covering the next 5 years and set the following targets for growth, profitability and efficiency, pursuing their achievement: revenue, high-single-digit growth; operating profit margin, at least 20%; ROIC, at least 10%; and ROE, at least 10%, to be maintained.」
Having completed the final year of the 5-year medium- to long-term growth strategy formulated in 2016, the Group transitioned to the new 5-year growth strategy, GS26, formulated in December 2021. The new target metrics were high-single-digit revenue growth, an operating profit margin of at least 20%, ROIC of at least 10% and ROE of at least 10%. - FY2022-Q3AdvancedAnnual report
「Adjusted operating profit increased 21.1% year on year to ¥107.2 billion, as the increase in gross profit exceeded the increase in selling, general and administrative expenses.」
As progress in profitability under the medium- to long-term growth strategy, cumulative adjusted operating profit for FY2022-Q3 increased 21.1% year on year. - FY2022-Q2AdvancedAnnual report
「Adjusted operating profit increased 44.6% year on year to ¥74.1 billion, as the increase in gross profit exceeded the increase in selling, general and administrative expenses.」
As progress in profitability under the 5-year medium- to long-term growth strategy, cumulative adjusted operating profit for FY2022-Q2 increased 44.6% year on year. - FY2022-Q1AdvancedAnnual report
「Adjusted operating profit increased 85.4% year on year to ¥40.2 billion, driven by higher gross profit.」
As progress in profitability under the medium- to long-term growth strategy, adjusted operating profit in FY2022-Q1 increased 85.4% year on year. Higher gross profit contributed to profit growth. - FY2021ReframedAnnual report
「In the fifth year, FY2021 (the fiscal year ending March 2022), the Group will pursue initiatives including “leveraging comprehensive capabilities and brand strength” to seek synergies among businesses in each region, “optimizing the global organization and operations,” “promoting digitalization and business model transformation,” “evolving human capital management” to visualize global human capital and strengthen expertise, and “deepening core technologies that represent strengths,” in order to achieve sustainable growth from that fiscal year onward.」
Looking toward the fifth year of the 5-year medium- to long-term growth strategy, the existing strategy was reorganized into 5 areas: comprehensive capabilities and brand strength, organizational and operational optimization, digitalization, human capital, and core technologies. - FY2021-Q2Deterioration in progress toward the growth strategy's performance targetsAnnual report
「Revenue decreased 7.8% year on year to ¥283.3 billion. Adjusted operating profit decreased 23.5% year on year to ¥51.3 billion, as the decline in gross profit outweighed partial reductions in selling, general and administrative expenses.」
In the fourth year of the 5-year medium- to long-term growth strategy, cumulative revenue decreased 7.8% and adjusted operating profit decreased 23.5% due to the impact of COVID-19, worsening short-term progress in growth and profitability. - FY2020AdvancedAnnual report
「In the fourth year, FY2020 (the fiscal year ended March 2021), the Group will pursue initiatives including “accelerating the global strategy,” “enhancing the product pipeline,” “strengthening and optimizing operations supporting growth,” including the production system, and “evolving the business model” to address challenges in customer activities, in order to achieve sustainable growth.」
Regarding the 5-year medium- to long-term growth strategy, the Company explained that FY2019, the third year, exceeded the initial profit forecast, and organized the measures for the fourth year into 4 areas: global strategy, pipeline, operations and business model. - FY2020-Q3AdvancedAnnual report
「Adjusted operating profit increased 7.9% year on year to ¥98.4 billion, driven by higher gross profit.」
As progress in profitability under the 5-year medium- to long-term growth strategy, adjusted operating profit for the 9 months ended the third quarter increased 7.9% year on year. - FY2020-Q2AdvancedAnnual report
「Adjusted operating profit increased 21.2% year on year to ¥67.0 billion, as higher gross profit more than offset slower progress in some selling, general and administrative expenses.」
As progress in profitability under the medium- to long-term growth strategy, adjusted operating profit for the 6 months ended the second quarter increased 21.2% year on year. - FY2019AdvancedAnnual report
「In the first year, FY2017 (the fiscal year ended March 2018), results from businesses acquired in the previous fiscal year also contributed, and the Group got off to a solid start toward achieving the targets of its medium- to long-term growth strategy. In the second year, FY2018 (the fiscal year ending March 2019), shipments of some products from the Cardiovascular Company's Aitaka Plant were delayed during the first half, but operations fully normalized in the second half, returning the business to a recovery trend, and all companies reported higher revenue.」
Regarding the 5-year growth strategy, the Company described steady progress in the first year, followed in the second year by a recovery from shipment delays and higher revenue at all companies. - FY2019-Q2RestatedAnnual report
「By viewing these emerging market needs as growth opportunities, the company aims to contribute to society through healthcare, its corporate philosophy, and to achieve sustainable and profitable growth. At the same time, it will drive innovation through product development that meets the needs of healthcare settings and strive to become a company with a strong presence worldwide.」
As directions related to the medium- to long-term growth strategy, the Group continues to emphasize sustainable and profitable growth, innovation through product development, and becoming a company with a strong global presence. - FY2018AdvancedAnnual report
「The first year, FY2017 (the fiscal year ended March 2018), got off to a solid start toward achieving the targets of “sales growth exceeding market growth” (a high-single-digit growth rate) and “profit growth exceeding sales growth” (a double-digit growth rate). In the second year, FY2018 (the fiscal year ending March 2019), negative effects from revisions to drug prices and prices for specially controlled medical materials, as well as higher amortization resulting from increased capital and IT investment for growth, are expected.」
For the 5-year medium- to long-term growth strategy, the first year was described as having got off to a solid start toward achieving the sales and profit growth targets. Measures for the second year were identified as strengthening global operations, strategic development and leveraging the Group's comprehensive capabilities. - FY2018-Q3RestatedAnnual report
「Against this backdrop, the Group is pursuing management based on a medium- to long-term vision of becoming a manufacturer trusted worldwide as a leading brand in healthcare, while earning world-class trust in total quality, including products, supply and services, as a “global company originating in Japan.”」
As visions related to the medium- to long-term growth strategy, the Group continues to pursue the direction of being a global company originating in Japan, total quality and a leading brand. - FY2018-Q1RestatedAnnual report
「Against this backdrop, the Group is pursuing management based on a medium- to long-term vision of becoming a manufacturer trusted worldwide as a leading brand in healthcare, while earning world-class trust in total quality, including products, supply and services, as a “global company originating in Japan.”」
As visions related to the medium- to long-term growth strategy, the Group continues to pursue the direction of being a global company originating in Japan, total quality and a leading brand. - FY2017AdvancedAnnual report
「In light of these changes in the business environment, the Group formulated a medium- to long-term growth strategy covering the next 5 years. Under its corporate philosophy of “contributing to society through healthcare,” the Group aims to pursue the following 3 strategies, enhance total quality across its products, supply and services, and provide value needed in healthcare settings worldwide, thereby establishing itself as a leading brand in each field in which it operates.」
The medium- to long-term growth strategy was defined through 3 specific initiatives: global selection and concentration, leveraging the Group's comprehensive capabilities in Japan, and promoting innovation. - FY2017-Q3First statedAnnual report
「Looking 10 years ahead, the Group formulated in December a medium- to long-term growth strategy covering the five years beginning April 2017.」
In December 2016, the Company formulated a medium- to long-term growth strategy covering the 5 years from April 2017.